Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

HOXA9/METTL3/BMI1 axis is required for promoting anthracycline resistance in acute myeloid leukemia cells by modulating BMI1 expression through  mRNA m6A modification

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHao WangDLDai-hong LiuLDLiping Dou

Discussion

Loading...

Member takes

Overview

Integrative analyses demonstrate that the HOXA9/METTL3/BMI1 axis regulates drug resistance, apoptosis, and prognosis in AML patients.

Key Points

  • This research aims to elucidate the mechanisms underlying anthracycline resistance in acute myeloid leukemia through the HOXA9/METTL3/BMI1 axis.
  • Utilized ATAC-seq to analyze chromatin accessibility in AML cells.
  • Conducted RNA-seq, qRT-PCR, and Western blot to assess METTL3 expression.
  • Applied small-molecule inhibitors and shRNA knockdown to investigate gene regulation.
  • Performed MeRIP-seq to identify METTL3 target genes and analyze m6A modifications.
  • Employed dual-luciferase reporter assays to confirm HOXA9 binding to the METTL3 promoter.
  • Over 50% of chromatin regions are accessible in anthracycline-sensitive AML, compared to less than 25% in resistant cases.
  • METTL3 expression is significantly elevated in drug-resistant cells, correlating with increased m6A modification and apoptosis suppression.
  • Knockdown of HOXA9 in resistant cells led to decreased proliferation and increased apoptosis, correlating with poor prognosis.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e036https://doi.org/10.1182/blood-2025-5246
View Full Paper
Ask AI
Bookmark
Share